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INTRODUCTION
Thrombocytopenia (TP) is a frequent complication after
allogeneic stem cell transplantation (SCT) (1-3). The prognos-
tic significance of the platelet count in patients with chronic
graft-versus-host disease (GVHD) has already been empha-
sized by several studies (3-6). In addition, persistent TP is
regarded as a poor prognostic factor in transplant patients
with chronic GVHD (3, 6). Bolwell et al. (7) also recently
reported that the platelet count at day +100 was strongly
associated with survival after allogeneic bone marrow trans-
plantation (BMT).
Various multi-factorial causes may be related to the devel-
opment of TP after allogeneic SCT (2), including GVHD,
graft-failure, drugs (e.g. ganciclovir, cyclosporin A, FK-506,
mycophenolate mofetil, trimethoprim/sulfamethoxazole),
veno-occlusive disease, cytomegalovirus infection, oppor-
tunistic infection, recurrence of the primary disease, or hemo-
lytic uremic syndrome/thrombotic thrombocytopenic pur-
pura (2). However, it is very difficult to decipher the precise
etiology of TP during the post-transplant period in a clini-
cal setting. Even, the presence of TP itself after allogeneic
SCT may impact on survival in transplant patients, regard-
less of the cause. Accordingly, the current study examined
the platelet count at day +60 to stratify patient groups accord-
ing to the platelet count, regardless of the etiology of TP, in
an allogeneic peripheral blood stem cell transplantation (PB-
SCT) setting.
MATERIALS AND METHODS
Transplantation procedure
Sixty-three consecutive adult patients who had undergone
allogeneic PBSCT (total 75 patients) and were evaluable on
day +60 at Kyungpook National University Hospital (Daegu,
Korea) between August 1998 and October 2003 were included
in this retrospective study. The enrolled hematological dis-
eases included acute myeloid leukemia (AML) (n=32), aplas-
tic anemia (AA) (n=9), chronic myeloid leukemia (CML)
(n=8), acute lymphoblastic leukemia (ALL) (n=5), lymphoma
(n=3), myelodysplastic syndrome (MDS) (n=2), myeloma
(n=2), paroxysmal nocturnal hemoglobinuria (PNH) (n=1),
and metastatic colon cancer (n=1) with 34 (54%) standard-
risk and 29 (46%) high-risk diseases. The median age of the
patients was 37.0 yr (range, 16-56 yr), and the male to female
ratio was 63:37% (n=40/23). The conditioning regimens
consisted of a BuCy-based (n=40), Cy/anti-thymocyte glob-
ulin (ATG) (n=9), and fludarabine-based regimen (n=13).
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Clinical Significance of Platelet Count at day +60 After Allogeneic
Peripheral Blood Stem Cell Transplantation
Thrombocytopenia (TP) is a frequent complication after allogeneic stem cell trans-
plantation (SCT) and regarded as a poor prognostic factor, especially in patients
with chronic graft-versus-host disease (GVHD), although various factors were relat-
ed to the development of TP after allogeneic SCT. Sixty-three patients receiving
allogeneic peripheral blood stem cell transplantation (PBSCT) were stratified accord-
ing to platelet count (PC) at day +60 and analyzed in terms of overall survival (OS)
and the incidence of non-relapse mortality (NRM). Ten patients (15.9%) were strati-
fied in group 1 (PC ≤29×10
9/L), 23 patients (36.5%) in group 2 (PC 30-79×10
9/L),
and 30 patients in group 3 (PC ≥80×10
9/L). Group 3 was associated with lower
incidence of extensive chronic GVHD (p=0.013), better 3-yr OS (p=0.0030), and
lower NRM rate (p<0.0001). In multivariate analyses, the PC at day +60 was iden-
tified as an independent prognostic factor (p=0.003) together with CD34+ cell dose
(p<0.001), disease risk (p=0.004), and acute GVHD (p=0.033) in terms of NRM,
and the PC (p=0.047) and CD34+ cell dose (p=0.026) in terms of incidence of infec-
tious events. Measuring the platelet count at day +60 is a simple method for predict-
ing the risk of chronic GVHD development and prognosis after allogeneic PBSCT.
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Myeloablative and reduced-intensity conditioning was adopt-
ed in 45 and 18 patients, respectively. All patients received
peripheral blood stem cells (PBSC)s mobilized with 10  g/
kg/day G-CSF (Filgrastim, Leukokine
�, CJ, Co., Seoul, Korea)
alone (n=11), 10  g/kg/day GM-CSF (Sargramostim, Leuco-
gen
�, LG, CI., Seoul, Korea) alone (n=10), a combination
regimen (n=42) of 5  g/kg/day G-CSF and 5  g/kg/day GM-
CSF for 4 or 5 days from 59 HLA-matched sibling donors
(93.7%) and 4 mismatched sibling donors (6.3%), as previ-
ously reported (8, 9). The leukapheresis was performed using
a Fenwal CS 3000+
� blood cell separator (Baxter, Healthcare,
Deerfield, IL, U.S.A.) with acid-citrate-dextrose as the anti-
coagulant (10). In the case of the 4 mismatched transplants,
3 patients received unmanipulated PBSCs, while 1 patient
received CD34+ cell selected PBSCs. For successful transplan-
tation, the minimum target number of mononuclear cells
(MNC)s and CD34+ cells was >3×108/kg and >3×106/
kg, respectively. An ATG infusion was conducted in 9 patients
(14.3%) as a part of the Cy/ATG conditioning and in 6 patients
(9.5%) as part of the reduced-intensity conditioning.
The prophylaxis against acute GVHD consisted of metho-
trexate (MTX) and cyclosporin A (CSA; Cipol-N
�, Chong-
KunDang, Seoul, Korea), except for 2 cases that used CSA/
mycophenolate mofetil (MMF; n=1) or CSA/MTX/MMF
(n=1). The infection prophylaxis consisted of ciprofloxacin
(250 mg twice a day orally [p.o.])/metronidazole (500 mg
three times a day p.o.)/fluconazole (100 mg once a day p.o.),
beginning with the initiation of conditioning, and acyclovir
(600 mg twice a day p.o.) from day-1 until day+180. Cotri-
moxazole was started after engraftment, and ursodeoxycholin-
ic acid was used for the veno-occlusive disease prophylaxis,
beginning with the initiation of conditioning. Intravenous
immunoglobulin (500 mg/kg) was infused every two weeks
until day+100, then every month until +6 months. All patients
received irradiated blood products that had been depleted of
leukocytes using filters.
Definitions
The day of the stem cell infusion was defined as day 0.
Engraftment was confirmed by peripheral blood counts (mye-
loid: peripheral absolute neutrophil count of more than 0.5
×109/L, megakaryocyte: peripheral platelet count of more
than 20×109/L for at least 3 consecutive days without requir-
ing transfusion). Overall survival (OS) was defined as the
time from transplantation until death from any cause. Dis-
ease-free survival (DFS) was defined as the time from trans-
plantation until relapse or death in complete remission (CR),
by whatever cause. The relapse incidence was defined as the
time from transplantation until relapse. Non-relapse mor-
tality (NRM) was defined as the time from transplantation
until death from infectious or GVHD-related causes. The
day of an infectious event was defined as the day when the
clinical symptom(s) or sign(s) of infection was first reported.
The causative organisms were identified by microbiologic or
histologic methods. High-risk diseases were defined as acute
leukemia that was more than the first CR or with extra-
medullary involvements, Ph+ acute lymphoblastic leukemia,
advanced phase chronic myelogenous leukemia, or primary
refractory or multiple relapsed malignancies. Acute and chronic
GVHD were diagnosed and graded using established crite-
ria (11, 12). Positive cytomegalovirus (CMV) antigenemia
was defined as any positive level in a CMV pp65 antigene-
mia assay. CMV disease was defined as a symptomatic CMV
infection. According to the platelet count at day +60, the
patients were classified into 3 groups. Group 1: platelet count
≤29×109/L, Group 2: platelet count 30-79×109/L, Group
3: platelet count ≥80×109/L. 
Statistics
The clinical characteristics and transplant outcomes of the
stratified groups were compared using Fisher’s exact test or
Kruskal-Wallis’s test. Survival analyses of OS, DFS, the relapse
incidence, incidence of NRM, and infectious events were
conducted using the Kaplan-Meier method. A log rank test
was also used for a survival analysis. Multivariate analyses of
Cox’s proportional hazard regression were applied to define
the risk factors for OS, DFS, the relapse incidence, and inci-
dence of NRM and infectious events using the backward
method. The variables included for the multivariate analyses
were as follows: the group according to the platelet count at
day +60, the age of patients, CD34+ cell counts (<6 vs. ≥6
×106/kg), conditioning (reduced-intensity conditioning vs.
myeloablative), donor status (HLA-matched sibling donors
vs. alternatives), disease status (standard- vs. high-risk), the
use of ATG (yes vs. no), acute GVHD (grade 0, 1 vs. grade
2-4), and chronic GVHD (yes vs. no). A cut off p-value of 0.05
was adopted for all statistical analyses. The statistical data were
obtained using an SPSS software package (SPSS 10.0 Inc.
Chicago, IL, U.S.A.). 
RESULTS
Patient characteristics
The patients’ characteristics are summarized in Table 1.
Out of the total 63 patients, 10 patients (15.9%) were clas-
sified in group 1 (platelet count ≤29×109/L), 23 patients
(36.5%) in group 2 (platelet count 30-79×109/L), and 30
patients (47.6%) in group 3 (platelet count ≥80×109/L).
No differences in the pre-transplant characteristics were found
among the 3 groups, except for the mobilization regimens
(p=0.051), where the GM-CSF alone mobilization regimen
was associated with a lower platelet count at day +60 com-
pared with the GM-/G-CSF combination regimen (p=0.038).
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7.37×106/kg (range 0.69-20.60) and 8.10×108/kg (range
1.69-22.30), respectively. No difference in the MNC dose
was noted among 3 groups, yet an association between the
CD34+ cell dose and the different groups was found, although
with a marginal significance (Table 1).
Measurement of platelet count at day +30, +60, and +90
The serial measurements of the platelet count revealed a
drop-and-rise pattern of platelet recovery from day +30 to
day +90 (Fig. 1). The mean platelet count at day +30, +60,
and +90 was 102.254 (95% confidence interval [C.I.] 81.820-
122.688), 84.302 (95% C.I. 70.115-98.488), and 111.281
(95% C.I. 94.279-128.283)×109/L, respectively.
Transplantation outcomes
The median engraftment day for neutrophils and platelets
was 15 days (range, 9-30 days) and 14 days (range, 9-81 days),
respectively. Eventually, 54 patients (85.7%) achieved a sta-
ble platelet engraftment (platelets≥50×109/L) with a medi-
an of 27 days post-transplant (range, 11-396 days). Forty-
nine (77.8%) out of the total 63 patients experienced acute
GVHD over grade 1 (29 patients: grade 2 acute GVHD, 14
patients: grade 3, 4 acute GVHD), while 40 (70.2%) out of
evaluable 57 patients experienced chronic GVHD and 19
patients (33.3%) extensive chronic GVHD.
Variable
Platelet 
count
≤29×10
9/L
Platelet 
count
30-79×10
9/L
Platelet 
count
≥80×10
9/L
p-
value
No. of pts (%) 10 (15.9%) 23 (36.5%) 30 (47.6%)
Sex (F/M) 4/6 (40/60) 8/15 (35/65) 11/19 (37/63) NS
Age (yr) 35.5 (18-46) 38.0 (18-56) 36.5 (16-54) 0.946
Diagnosis
AML/ALL 4/3 13/1 15/1 0.322
CML/MDS 1/0 3/1 4/1
AA/PNH 0/0 3/0 6/1
NHL/Myeloma 1/1 0/1 2/0
CRC 0 1 0
High risk 6 (60) 10 (44) 13 (43) NS
Conditioning
BuCy-based 9 (90) 16 (70) 15 (50) NS
Cy/ATG 0 (0) 3 (13) 6 (20)
Fludara-based 1 (10) 4 (17) 9 (30)
Reduced intensity 2 (20) 5 (22) 11 (37) NS
ATG-containing 1 (10) 7 (30) 7 (23) NS
Mobilization
GM-CSF alone 4 (40) 4 (17) 2 (7) 0.051
G-CSF alone 3 (30) 3 (13) 5 (17)
GM-/G-CSF 3 (30) 16 (70) 23 (76)
Stem cell, infused
MNC (×10
8/kg) 6.76 9.36 7.54 0.263
(2.82-13.43) (1.69-16.03) (4.08-22.30)
CD34+ (×10
6/kg) 4.94 8.18 7.84 0.093
(2.22-16.89) (0.69-19.56) (3.80-20.60)
Table 1. Summary of patients’ characteristics and transplanta-
tion procedures according to platelet count on day +60 post-
transplant
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML,
chronic myeloid leukemia; MDS, myelodysplastic syndrome; AA, aplastic
anemia; PNH, paroxysmal nocturnal hemoglobinuria; NHL, non-Hodgkin’s
lymphoma; CRC, colon cancer, metastatic; Fludara, Fludarabine; ATG,
anti-thymocyte globulin; MNC, mononuclear cell.
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Fig. 1. Serial measurement of platelet count on day +30, +60, and
+90 post-transplant.
Variable
Platelet 
count
≤29×10
9/L
Platelet 
count
30-79×10
9/L
Platelet 
count
≥80×10
9/L
p-
value
No. of pts (%) 10 (15.9%) 23 (36.5%) 30 (47.6%)
ANC (days) 18.5 (12-25) 15.0 (9-25) 14 (10-24) 0.059
Platelet (days) 23.0 (12-81) 15 (9-56) 14 (10-24) 0.001
Acute GVHD
Overall 7 (70) 17 (74) 25 (83) NS
Grade 2-4 7 (70) 17 (74) 19 (63) NS
Grade 3, 4 5 (50) 7 (30) 2 (7) 0.001
Chronic GVHD n=6 n=21 n=30
Overall 5 (83) 17 (81) 18 (60) NS
Progressive onset 3 (50) 9 (43) 7 (23) NS
Extensive 4 (67) 9 (43) 6 (20) 0.013
Infectious events
CMV reactivation 5 (50) 12 (52) 13 (43) NS
CMV treatment 2 (20) 1 (4) 0 (0) 0.029
Infectious events 6 (60) 8 (35) 10 (33) NS
Survival
Recurrence 3 (30) 5 (22) 14 (47) NS
Death 8 (80) 11 (48) 12 (40) 0.086
NRM 6 (60) 7 (30) 3 (10) 0.005
Infection 2 (20) 3 (13) 1 (3)
Infection+GVHD 3 (30) 3 (13) 1 (3)
GVHD 1 (10) 1 (4) 1 (3)
Table 2. Summary of transplant outcomes according to platelet
count on day +60 post-transplant
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When last assessed with a median follow-up duration of
340 days (range 56-1,839 days; 755 days among survivors
with range of 107 to 1,839 days), 22 relapses (34.9%) and
31 deaths (49.2%), including 16 NRM cases (25.4%), were
recorded. The causes of death included relapse (n=15, 48.4%),
infection (n=12, 38.7%), and GVHD-related death (n=4,
12.9%). The 1- and 3-yr OS rates were estimated as 49.0±
6.0% and 43.2±6.2%, respectively, while the 1- and 3-yr
DFS rates were estimated as 40.1±5.9% and 35.9±6.0%,
respectively. The cumulative incidence of relapse after 1 and
3 yr was estimated as 39.4±6.6% and 42.8±7.0%, respec-
tively, while that of NRM after 1 and 3 yr was 34.9±6.1%
and 40.3±6.6%, respectively. The cumulative incidence of
overall infectious complications beyond day +60 (n=31) was
19.7±4.7% on day +100 and 44.5±6.5% on day +365.
The median onset of infectious complications after day +60
was 176 days post-transplant (range 63-704 days). The cumu-
lative incidence of bacterial complications (n=19) was 15.5
±4.3% on day +100 and 26.7±5.7% on day +365, while
that of viral infection (n=12) was 3.8±2.0% on day +100
and 18.1±5.6% on day +365, and that of fungal infection
(n=3) was 1.7±1.6% on day +100 and 6.3±3.6% on day
+365.
Outcomes according to platelet count at day +60
The transplantation outcomes according to the platelet
count at day +60 are summarized in Table 2. Differences
were noted in the incidence of severe acute GVHD (grade
3, 4; p=0.001) and extensive chronic GVHD (p=0.013) among
the 3 groups. Group 1 showed a higher incidence of severe
acute GVHD (50% for group 1 vs. 30% for group 2 vs. 7%
for group 3) and extensive chronic GVHD (67% for group
1 vs. 43% for group 2 vs. 20% for group 3) compared to the
other 2 groups.
Meanwhile, group 3 was associated with a significantly
better 3-yr OS (60.3±9.9% for group 3 vs. 45.8±11.3%
for group 2 vs. 13.3±12.0% for group 1, p=0.0030, Fig. 2A)
and DFS (48.7±10.0% for group 1 vs. 41.7±11.3% for
group 2 vs. 15.0±12.8% for group 1, p=0.0076). There was
no difference in the relapse incidence among the 3 groups
(51.3±9.9% for group 1 vs. 23.7±9.5% for group 2 vs.
40.0±19.7% for group 1, p=0.2825), while group 3 was
associated with a lower 3-yr NRM rate (11.1±7.5% for
group 3 vs. 42.8±12.6% for group 2 vs. 84.0±14.2% for
group 1, p<0.0001, Fig. 2B).
In the analysis of the causes of death, there was no differ-
ence in the mortality due to disease progression among the
groups, yet a distinct difference in the mortality due to NRM
(Table 2). Ten percent of group 3 died of NRM, while 30%
and 60% of groups 2 and 1 died of NRM, respectively (p=
0.005). The cause of NRM was shown in Table 2.
Multivariate analyses
The results of the multivariate analyses for prognostic fac-
tors are shown in Table 3. In terms of OS, the stratified groups
according to the platelet count at day +60 were identified
as an independent prognostic factor (p=0.003) together with
the CD34+ cell dose (p=0.001), disease risk (p<0.001), and
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Fig. 2. Overall survival and cumulative incidence of non-relapse
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development of chronic GVHD (p<0.001). For NRM, the
stratified groups were also identified as an independent prog-
nostic factor (p=0.003) together with the CD34+ cell dose
(p<0.001), disease risk (p=0.004), and development of acute
GVHD (p=0.033). Furthermore, the results of the multivari-
ate analyses for the cumulative incidence of infectious events
identified that the stratified groups according to the platelet
count at day +60 were an independent prognostic factor (p=
0.047) together with the CD34+ cell dose (p=0.026).
DISCUSSION
TP is known to have a prognostic significance in patients
receiving allogeneic SCT (1-3). The most important mecha-
nism involved in the development of TP after allogeneic SCT
is a GVHD-related event, including autoimmune (ITP-like)
destruction, immune regulation, or viral-induced suppres-
sion of platelet production. Anasetti et al. (13) reported that
TP developed most frequently secondary to increased platelet
destruction mediated by platelet auto-antibodies in an allo-
geneic setting. Meanwhile, Nash et al. (2) reported an asso-
ciation with delayed platelet recovery in two common situa-
tions (GVHD and infection) after allogeneic SCT, causing a
decreased platelet survival in the peripheral circulation. They
also proposed that elevated cytokines, including G-CSF, M-
CSF, IL-1 , IL-1 , and IL-6, may contribute to the activa-
tion of monocytes and macrophages that are critical compo-
nents for the elimination of platelets. As such, cytokine-in-
duced thrombocytopenia could offer another explanation for
platelet consumption after allogeneic SCT as an non-autoim-
mune mechanism (2).
First et al. (1) previously described two distinct thrombo-
cytopenic syndromes, transient and persistent TP. Transient
TP, where a normal platelet count (>100×109/L) is initial-
ly established by day +40, which then diminishes to <10 to
45×109/L on day +40 to +70 with subsequent resolution
of the TP by day +90, has no adverse affect on the prognosis,
whereas persistent TP, where a platelet count >100×109/L
is not achieved at any time during the first 4 months post-
transplant, carries a high mortality and high association with
both severe acute and chronic GVHD. During the post-trans-
plant period until day +100, several clinical events predispos-
ing the development of TP tend to occur simultaneously,
thus, it is very important to decipher the precise etiology of
TP in the post-transplant period. In the current study, day
+60 was adopted as a landmark day to determine the prog-
nostic role of the platelet count after allogeneic SCT, as day
+60 effectively reflects the ‘‘dip period’’ of the platelet count
(day +40-day +70) in terms of post-transplant platelet recov-
ery (1). As such, it was found that TP at day +60 was asso-
ciated with the prognosis of patients in terms of NRM and
infectious events, opportunistic infections, and an association
with severe acute GVHD and extensive chronic GVHD,
regardless of the etiology of TP. Therefore, this finding implies
that the platelet count at day +60 can play a prognostic role
for patients receiving allogeneic SCT and reflect the proba-
bility of infectious events and NRM, even before the devel-
opment of chronic GVHD.
The use of PBSC is associated with less regimen-related
toxicity and earlier hematologic recovery without an increase
in acute GVHD, yet concerns remain in relation to chronic
GVHD adversely affecting OS and NRM (14). In a study
by Przepiorka et al. (14), the incidence of clinical extensive
GVHD in allogeneic PBSCT was 67%, which was higher
than that in allogeneic BMT. As such, the incidence of TP
(80×109/L) may also be anticipated to be higher in relation to
GVHD in an allogeneic PBSCT setting than in a BMT set-
ting. In the current study on allogeneic PBSCT, the incidence
of chronic GVHD and TP was relatively high compared with
previous reports on allogeneic BMT. This disadvantage can
be translated into frequent use of intensive immunosuppres-
sions for profound GVHD, which in turn can increase the
incidence of infectious events. In the present study, the most
common cause of NRMs was opportunistic infection in throm-
bocytopenic patients (50% vs. 26% vs. 3%; Table 2). Accord-
ing to Bolwell et al. (7), thrombocytopenic patients at day
+100 after allogeneic BMT had a far lower risk of dying of
infection than dying of GVHD. However, in trials with allo-
Variable
Hazard 
ratio
p-
value
95% Confi-
dence interval
Overall survival
Thrombocytopenia at day +60 - 0.003 -
≤29×10
9/L vs. ≥80×10
9/L 2.515 0.033 1.076,  5.875
30-79×10
9/L vs. ≥80×10
9/L 1.415 0.307 0.726, 2.757
Lower CD34+ cells, infused 5.258 0.001 2.047, 13.504
High risk disease 2.236 <0.001 1.432, 3.490
Chronic GVHD, No. 6.490 <0.001 2.268, 18.570
Disease-free survival
Thrombocytopenia at day +60 - 0.073 -
≤29×10
9/L vs. ≥80×10
9/L 2.793 0.033 1.076,  5.774
30-79×10
9/L vs. ≥80×10
9/L 0.776 0.415 0.421, 1.428
Lower CD34+ cells, infused 3.554 0.003 1.550, 8.146
High risk disease 2.233 <0.001 1.441, 3.459
Chronic GVHD, No. 7.890 <0.001 2.978, 20.906
Non-relapse mortality
Thrombocytopenia at day +60 - 0.003 -
≤29×10
9/L vs. ≥80×10
9/L 3.215 0.022 1.179, 8.764
30-79×10
9/L vs. ≥80×10
9/L 3.184 0.016 1.241, 8.169
Lower CD34+ cells, infused 54.082 <0.001 6.275, 466.081
High risk disease 3.605 0.004 1.492, 8.710
Acute GVHD, grade 0, 1 8.397 0.033 1.191, 59.221
Incidence of infectious events
Thrombocytopenia at day +60 - 0.047 -
≤29×10
9/L vs. ≥80×10
9/L 2.047 0.032 1.012, 4.462
30-79×10
9/L vs. ≥80×10
9/L 0.863 0.188 0.463, 1.728
Lower CD34+ cells, infused 2.746 0.026 1.129, 6.680
Table 3. Cox regression model of effect of platelet count on day
60 for overall and disease-free survival, relapse incidence, non-
relapse mortality, and incidence of infectious eventsPlatelet Count at day +60 After Allogeneic PBSCT 51
geneic PBSCT, the incidence of extensive chronic GVHD
has been found to be higher than that in a BMT setting,
thereby facilitating the use of more intensive immunosup-
pressive therapy that has adverse effects on the incidence of
opportunistic infection and NRM. As such, in an allogeneic
PBSCT setting, more effort is needed to predict high-risk
patients in terms of chronic GVHD and opportunistic infec-
tion than in a BMT setting. Accordingly, measuring the plate-
let count at day +60 would appear to be a simple method for
stratifying patients according to their risk of chronic GVHD,
infection, and NRM.
However, the caution is needed in the interpretation of
the current study. More inclusion of the patients with aplas-
tic anemia into group 2 or 3 than group 1 might influence
on the outcomes, even though statistically insignificant (p=
0.387). Accordingly, further study will be needed to reach a
clear conclusion on this issue with homogeneous disease pop-
ulation.
TP after allogeneic SCT is a worrisome problem requiring
significant care. Available practices to manage TP after allo-
geneic SCT include preventing or treating the precipitating
factors increasing the consumption or destruction of platelets,
such as GVHD or infection. Bolwell et al. (7) recommended
more intensive immunosuppressive treatment or alternative
GVHD clinical trials for patients with TP and ongoing GV-
HD in the absence of active infections. In addition, given
the results of the current study, infection surveillance or pro-
phylaxis with antibiotics or antifungal agents may also be
beneficial for patients with TP at day +60 post-transplant.
In conclusion, measuring the platelet count at day +60 is
a simple method for predicting the risk of chronic GVHD
development and the prognosis of recipients in terms of OS
and NRM after allogeneic PBSCT. Patients with TP at day
+60 were found to have a higher risk of NRM and infectious
events that had an adverse affect on long-term survival after
allogeneic PBSCT.
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